Back to Home
Video

Module 3: Chronic Lymphocytic Leukemia (CLL)

Release Date

April 16, 2026

Expiration Date

March 1, 2027

Credits

1.0 CME, NCPD

Specialties

Hematologic Cancer, Hematology

Activity Overview

This educational activity is an archive of the live conference held from February 26, 2026, through February 28, 2026.

Target Audience 

This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies may also participate.

Learning Objectives

Upon participation in this activity, learners will be better able to:

  • Evaluate recent clinical trial results on approved and emerging therapeutic approaches for patients with hematologic disorders
  • Describe best practices for mitigating and managing treatment-related adverse events in patients with hematologic disorders
      Module 3: Chronic Lymphocytic Leukemia (CLL)

      GET STARTED WITH THIS PROGRAM:

      Register now to gain access to this program.

      Create AccountAlready Registered? Login Here

      Accreditation/Credit Designation

      Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

      Acknowledgment of Commercial Support

      This activity is supported by educational grants from Ascentage Pharma Inc; AstraZeneca Pharmaceuticals; Autolus Therapeutics; Daiichi Sankyo, Inc; Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals Corporation; PharmaEssentia; Rigel Pharmaceuticals, Inc; and Sanofi.

      Follow Us on Social Media!

      Related Content

      Course

      Module 3: Chronic Lymphocytic Leukemia (CLL)

      Create Account